Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324707 | 0.91 | KCNH2 (0.44) | CHRM2CHRM4CHRM5KCNH2OPRK1 | |
| SCHEMBL23003594 | 0.86 | LTA4H (0.49) | KCNH2OPRK1OPRM1LTA4HMEN1 | |
| SCHEMBL14016385 | 0.86 | L3MBTL1 (0.48) | CHRM2CHRM4CHRM5KCNH2OPRK1 | |
| SCHEMBL928276 | 0.83 | ARG1 (0.45) | CHRM2CHRM4CHRM5KCNH2OPRK1 | |
| SCHEMBL5832412 | 0.82 | CYP2D6 (0.47) | KCNH2OPRK1OPRM1OPRD1L3MBTL1 | |
| SCHEMBL26694901 | 0.80 | SIGMAR1 (0.44) | CHRM2CHRM4CHRM5 | |
| SCHEMBL4832341 | 0.80 | BRD4 (0.48) | CHRM2CHRM4CHRM5LMNAALDH1A1 | |
| SCHEMBL19838851 | 0.80 | KMT2A (0.57) | KCNH2OPRK1OPRD1L3MBTL1KMT2A | |
| SCHEMBL19838852 | 0.80 | KMT2A (0.57) | KCNH2OPRK1OPRD1L3MBTL1KMT2A | |
| SCHEMBL4692043 | 0.80 | ALDH1A1 (0.45) | KCNH2L3MBTL1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| US-7348343-B2 | Amides useful for treating pain | ABBOTT LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070010557-A1 | Novel amides useful for treating pain | ABBVIE INC. | 2007-01-11 | — | — | US | disclosed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009841-A1 | Novel amides useful for treating pain | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009841-A1 | Novel amides useful for treating pain | OPRL1, OPRK1, FAAH2 | CHRM2 393/4885CHRM4 609/4885CHRM5 714/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | CHRM2 4089/4885CHRM4 3186/4885CHRM5 3725/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | CHRM2 4118/4885CHRM4 3129/4885CHRM5 3728/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | CHRM2 334/4885CHRM4 428/4885CHRM5 309/4885 |
| US-20070010557-A1 | Novel amides useful for treating pain | OPRL1, PDE6B, PDE6G | CHRM2 486/4885CHRM4 1180/4885CHRM5 573/4885 |
| US-20080153809-A1 | NOVEL AMIDES USEFUL FOR TREATING PAIN | OPRL1, OPRK1, OPRD1 | CHRM2 136/4885CHRM4 382/4885CHRM5 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.